AstraZeneca boosts COVID portfolio with RQ Bio deal
AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
U.S. to allow baby formula imports amid nationwide shortage
/in Abbott, Babies, Business, Congress, Facilities, FDA, Imports, Infant Formulas, Ireland, United States, White HouseThe United States will allow baby formula imports from foreign makers that do not usually sell their products here, the Food and Drug Administration said on May 16, as it tries to ease a nationwide shortage that has left parents scrambling to feed their babies.
Coronavirus may be linked to cases of severe hepatitis in children
/in Children, COVID-19 Studies, Hospitalized COVID-19 Patients, JAMA, Kids, Liver dysfunction, Medical Journals, Oxygen Therapy, R&D, Researchers, SARS-CoV-2 virus, Severe hepatitis, The Lancet Gastroenterology & HepatologyA chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis reported in hundreds of young children around the world, researchers suggest.
FDA declines to authorize common antidepressant as COVID treatment
/in Antidepressants, Brazil, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, FDA, Fluvoxamine, Generics, Selective Serotonin Reuptake Inhibitors (SSRIs), TherapeuticsThe U.S. Food and Drug Administration decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying the data has not shown the drug to be an effective therapeutic for fighting the virus.
FDA to soon authorize Pfizer’s COVID booster shot for younger kids – NYT
/in BNT162b2 (Pfizer and BioNTech), CDC, Children 5-11 Years, Clinical Trials, COVID-19 booster shots, Covid-19 Data, COVID-19 Vaccines, Emergency Use Authorization (EUA), FDA, New York Times, R&DU.S. health regulators are expected to authorize a booster shot of Pfizer/BioNTech’s COVID-19 vaccine for children aged 5 to 11 as soon as May 17, the New York Times reported on May 16, citing people familiar with the matter.
Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
/in Abbott, Business, FDA, Healthcare Companies, Infant Formulas, Infants, Ireland, Manufacturing Plants, Michigan, U.S. Department of Agriculture.Abbott agreed to enter into a consent decree with the U.S. Food and Drug Administration related to the company’s Sturgis, Mich., infant formula plant. The decree is an agreement between the FDA and Abbott on the steps necessary to resume production and maintain the facility. This does not affect any other Abbott plant or operation. The decree is subject to court approval.
Lacking vaccines, North Korea battles COVID with antibiotics, home remedies
/in Antibiotics, Coronavirus, Coronavirus, COVID-19 cases, Epidemics, Medical Supplies, North Korea, OutbreaksStanding tall in bright red hazmat suits, five North Korean health workers stride towards an ambulance to do battle with a COVID-19 outbreak that – in the presumed absence of vaccines – the country is using antibiotics and home remedies to treat. The isolated state is one of only two countries yet to begin a vaccination campaign and, until last week, had insisted it was COVID-free. Now North Korea is mobilizing forces including the army and a public information campaign to combat what authorities have acknowledged is an “explosive” outbreak.
Sofinnova Nets $1B+ from Apollo to Accelerate Biotech Growth
/in Assets, Biotech/Biopharma, Business, Collaborations, Inflammasome Inhibitors, Investments, Life Sciences, Partnerships, VenturesLeading life sciences venture firm Sofinnova Partners entered into a long-term strategic and financial partnership with Apollo, a high-growth, alternative asset manager looking to expand its presence in the life sciences.
Positive Clinical Results Advance Treatments For Multiple Myeloma, Asthma, Alzheimer’s
/in Alzheimer’s disease, Asthma, AstraZeneca, Biotech/Biopharma, Blood Tests, Clinical Data, Clinical Trials, Hematological Cancers, Lung Disease, Multiple myeloma, Neurodegenerative Disorders, New England Journal of Medicine, R&D, Sanofi, TherapeuticsIn recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
Shanghai targets June COVID lockdown exit as China economy slumps
/in China, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Restrictions, Coronavirus surge, COVID guidelines, Covid-19 Airborne Transmission, COVID-19 booster shots, COVID-19 cases, Covid-19 fatality rate, COVID-19 Lockdown Measures, COVID-19 Prevention Measures, COVID-19 protocols, Covid-19 Quarantine, COVID-19 recommendations, COVID-19 risk, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 transmission, COVID-19 vaccination rates, Covid-19 Variants, Mask-wearing, Pandemics, Shanghai, TherapeuticsShanghai set out plans on May 16 for the end of a painful COVID-19 lockdown that has lasted more than six weeks, heavily bruising China’s economy, and for the return of more normal life from June 1.